← FDA DRUG APPROVALS

FDA ANDA · ANDA074163

NAPROXEN

Sponsor: WATSON LABS TEVA

APPLICATION
ANDA074163
TYPE
ANDA
ORIGINAL APPROVAL
1995-02-10
LATEST ACTION
2001-08-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NAPROXENDiscontinued
NAPROXEN 375MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 500MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 250MG · TABLET · ORAL

Approval history

2001-08-24Manufacturing (CMC) · Supplement 8AP
2001-04-25Manufacturing (CMC) · Supplement 9AP
2000-02-03Manufacturing (CMC) · Supplement 7AP
2000-02-03Manufacturing (CMC) · Supplement 5AP
2000-02-03Manufacturing (CMC) · Supplement 6AP
1999-03-04Manufacturing (CMC) · Supplement 3AP
1999-03-04Manufacturing (CMC) · Supplement 2AP
1995-07-13Labeling · Supplement 1AP
1995-02-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →